Prediction of nanoparticle prodrug metabolism by pharmacokinetic modeling of biliary excretion. - Wikidata - awgldk - TriplyDB

Prediction of nanoparticle prodrug metabolism by pharmacokinetic modeling of biliary excretion.

Prediction of nanoparticle prodrug metabolism by pharmacokinetic modeling of biliary excretion.

http://www.wikidata.org/entity/Q37210032

about

Stable isotope method to measure drug release from nanomedicines.Comparison of two methods forecasting binding rate of plasma protein.Tanshinol borneol ester on nanostructured lipid carriers has longer brain and systemic effector retention and better antioxidant activity in vivo.

P2860

Q36395612-25302993-0A82-4C72-812D-7DFA0F65CB89 Q39139166-EC8E3609-9415-4D7A-AFBA-6B0241AE75F4 Q55003285-F27B6A8A-B63E-470A-A5DF-19CFC61E5EF1

P2860

Prediction of nanoparticle prodrug metabolism by pharmacokinetic modeling of biliary excretion.

http://www.wikidata.org/entity/Q37210032

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 09 May 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Prediction of nanoparticle pro ...... modeling of biliary excretion.

@en

Prediction of nanoparticle pro ...... modeling of biliary excretion.

@nl

type

label

Prediction of nanoparticle pro ...... modeling of biliary excretion.

@en

Prediction of nanoparticle pro ...... modeling of biliary excretion.

@nl

prefLabel

Prediction of nanoparticle pro ...... modeling of biliary excretion.

@en

Prediction of nanoparticle pro ...... modeling of biliary excretion.

@nl

P1433

Q37210032-37387E8D-281A-4BE9-977E-AD7C0D16413C

P1476

Q37210032-F023F283-C1E7-4A46-86FD-072BA3CD14D9

P2093

Q37210032-10A05719-766B-4616-AF43-FFF73BAEAE5E

Q37210032-35AA3D76-931D-4340-91AA-BF12F39E47B2

Q37210032-36C16A48-E51E-49F0-9C90-0B3090345F9C

Q37210032-3FFB812B-4DAD-4C6B-AE12-457466BD448C

Q37210032-4CF00FF1-7AC8-46A7-A1E4-D36C2DDB4AB1

Q37210032-803F130F-D18F-4432-887C-073E0F35A4BB

Q37210032-A5852F76-B018-4FED-B4AF-E015CA705F9A

Q37210032-EEFCC5C1-C863-41AB-B707-01BB0FB2B31A

Q37210032-F930EAF4-E9A1-448A-A52A-51C748EE0CFB

P2860

Q37210032-10CC1CCA-C1FA-4426-BA33-BA81A597E316

Q37210032-11E83387-23C7-4549-B5CD-ACDFF8EDF818

Q37210032-37CE275E-24FA-4567-9F17-CB70BD47A58D

Q37210032-3E01112B-5081-45DF-ACA1-9BED6588B8F1

Q37210032-5B78E7CC-5A2D-4DC1-B37A-9B88C6AF64B4

Q37210032-64D94FFD-4328-4334-BBBF-1E0F13F86B60

Q37210032-687024C6-9E04-4AF4-A075-04D5F33086E2

Q37210032-6A74A340-7217-4DBD-8D39-6AA7E7BA7BAA

Q37210032-94D3B048-9FC8-42A7-852A-E1734CAC5006

Q37210032-9581E0D2-84D0-420A-9A09-0A5DCC4D661A

P304

Q37210032-3329ED40-F8C2-4E42-A57E-1E128E54E899

P31

Q37210032-E6082EDB-415F-4AA3-BDA6-992EC3B359D3

P356

Q37210032-D4404282-22A5-424E-AA55-F25C770D4E64

P407

Q37210032-AD8C9DFE-A227-4FEB-90BE-E7FC12774BAA

P433

Q37210032-D0CE4B8B-5757-4426-B555-36308E5E74C7

P478

Q37210032-C7560A52-C179-4284-8348-488D4DA6E127

P577

Q37210032-A4C9B050-51BF-485A-9936-1F711FDB5BF8

P698

Q37210032-CBE52A5F-62F0-41BB-ADC0-90A5BC149F96

P921

Q37210032-1569E7AC-4BF9-4114-9DF3-D9FA06BD00F2

P932

Q37210032-6FDA4B2E-A7F5-4D86-9A40-13E46A08719A

P356

J.JCONREL.2013.04.025

P1433

Journal of Controlled Release

P1476

Prediction of nanoparticle pro ...... modeling of biliary excretion.

@en

P2093

Barry Liboiron

http://www.w3.org/2001/XMLSchema#string

Lawrence D Mayer

http://www.w3.org/2001/XMLSchema#string

Paul Tardi

http://www.w3.org/2001/XMLSchema#string

Peng Zou

http://www.w3.org/2001/XMLSchema#string

Sarah Skoczen

http://www.w3.org/2001/XMLSchema#string

Scott E McNeil

http://www.w3.org/2001/XMLSchema#string

Sherwin Xie

http://www.w3.org/2001/XMLSchema#string

Stephan T Stern

http://www.w3.org/2001/XMLSchema#string

Troy Harasym

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical pharmacokinetics of docetaxel.

Phase I study of the novel taxane CT-2103 in patients with advanced solid tumors.

Prediction of hepatic clearance in human from in vitro data for successful drug development.

Pharmacokinetic modeling and prediction of plasma pyrrole-imidazole polyamide concentration in rats using simultaneous urinary and biliary excretion data.

Translational considerations for cancer nanomedicine.

Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile.

Flip-flop pharmacokinetics--delivering a reversal of disposition: challenges and opportunities during drug development

The formulation of aptamer-coated paclitaxel-polylactide nanoconjugates and their targeting to cancer cells

Factors affecting toxicity and efficacy of polymeric nanomedicines.

Enzymatic activation of second-generation dendritic prodrugs: Conjugation of self-immolative dendrimers with poly(ethylene glycol) via click chemistry.

P304

558-567

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JCONREL.2013.04.025

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

172

http://www.w3.org/2001/XMLSchema#string

P577

2013-05-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23664969

http://www.w3.org/2001/XMLSchema#string

P921

P932

3788091

http://www.w3.org/2001/XMLSchema#string